In this study, we were concerned with the effect of probenecid on the pharmacokinetics of 1,000 mg of cefmenoxime administered over a 30-min period by intravenous infusion. Each of a total of 10 subjects received cefmenoxime twice, once with and once without adjunctive probenecid. The data were fit by iterative nonlinear regression procedures to a two-compartment open pharmacokinetic model, with elimination from the central compartment. The mean calculated peak concentration, area under the curve from zero to infinity, and half-life without probenecid were 78.1 pg/ml, 77.2 zg h/ml, and 1.14 h, respectively. When cefmenoxime was administered with probenecid, these values were 86.7 ,i.g/ml, 158.2 ,ug * h/ml, and 1.78 h, respectively. Averages of about 55 and 46% of the administered doses were recovered in urine samples collected at 0 through 24 h for doses administered without and with probenecid, respectively. The mean corrected renal drug clearance was 159 and 66 ml/min without and with probenecid, respectively. Statistical significance (P < 0.05) was demonstrated for the differences in beta half-life, (K/net), calculated peak concentration, area under the curve from 0 to infinity, and renal clearance, but not for K21, K12, volume of distribution, or alpha-phase distribution rate constant. The results of this study indicate that tubular secretion is the predominant mechanism of clearance for cefmenoxime and that probenecid alters the pharmacokinetics of the compound by competitively inhibiting its tubular secretion without affecting either the rate or
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Probenecid [p-(dipropylsulfamoyl) benzoic acid] has been found to inhibit the tubular secretion of a variety of weak organic acids (e.g., para-aminohippuric acid, chlorothiazide, phenolsulphonphthalein, salicylic acid, pantothenic acid) (1) (2) (3) 8) . It has been widely used as a uricosuric agent and as an adjunct to therapy with penicillin and other antibiotics to enhance antibacterial concentrations in plasma (4). In cases in which different elimination mechanisms appear to predominate (e.g., moxalactam, ceforanide) (5, 9) , probenecid has no significant effect on drug kinetics. In this study, we examined the effect of probenecid on the pharmacokinetics of cefmenoxime (also designated SCE-1365), a new semisynthetic broad-spectrum cephalosporin, in normal volunteers.
MATERIAS AND METHODS Volunteers. Ten normal adult male volunteers participated in this study after signing written statements of informed consent. The study was approved by the University of Utah Internal Review Board. The subjects were deemed healthy on the basis of a pre-drug screening, which included hematology, chemistry, urinalysis, medical history, physical examination, chest X-ray, and direct Coombs test. All tests were repeated after each dose was administered. Members of the group ranged in age from 19 to 40 years (mean, 27), in height from 67 to 72 inches (mean, 69), and in weight from 148 to 188 pounds (mean, 161).
Study design. The 10 subjects were randomly apportioned into two groups of 5 subjects each. On the first dosing day, all subjects received 30-min intravenous infusions of 1,000 mg of cefmenoxime dissolved in 50 ml of normal saline. Subjects 6 through 10 also received 500 mg of probenecid orally, 7 and 1 h before and 5 h after the start of the infusion, for a total of 1,500 mg of probenecid. All infusions were conducted with an infusion pump (model 927; IMED Corp., San Diego, Calif.). All of the data were readily fitted to the selected model ( Table 2 ). The differences in K12, K21, volume of distribution of the central compartment, and alpha-phase distribution rate constant between the two groups were not significant at a confidence level of P = 0.05. The mean beta half-life without probenecid was 1.14 h, which was extended to 1.78 h with probenecid. The data show consistently higher circulating cefmenoxime levels with adjunctive probenecid treatment. Analyses of variance indicated the differences between the two groups of Table 1 to be significant (P < 0.01) at all sampling times from 0.25 through 12 h after the start of the infusion.
A summary of the mean urinary excretion data for the two dose groups is shown in Table 3 . The differences between the total amounts of cefmenoxime excreted by the two groups was statistically significant (P < 0.05). Table 4 shows a summary of the uncorrected renal clearance of cefmenoxime, calculated from the data of Tables  1 and 3 . If it is assumed that the 77% plasma protein binding reported in the literature for cefmenoxime (10) is applicable to this experimental situation, it can be seen that the corrected renal clearances for the group without probenecid were consistently higher than the normal glomerular filtration rate (ca. 120 ml/min). Indeed, an analysis of variance of the corrected renal clearances of the two groups showed them to be significantly different (P = 0.0001). The mean value (± standard deviation) without probenecid was 159 ± 38 ml/min, a value which, with probenecid, was reduced to 66 ± 14 mIlmin. Thus, tubular secretion would appear to be the predominant mechanism of elimination, consistent with earlier interpretations (7) . The data of Table 3 The fact that significantly smaller fractions of the administered cefmenoxime doses were excreted in the urine when the drug was administered with probenecid, as compared with the fractions excreted when the drug was administered alone, could be the result of at least two phenomena: the increased half-life of cefmenoxime in plasma might have resulted in the compound undergoing a small amount ofbiotransformation (metabolic or nonmetabolic) in the circulation during the increased residence time, or it might have allowed a larger fraction of the dose to undergo biliary secretion, thus being lost into the feces. This latter explanation would be consistent with results obtained in our laboratory (unpublished data), in which about 11% of an administered dose of radiolabeled cefmenoxime was found to undergo biliary secretion in humans; however, probenecid is known to inhibit the active biliary secretion of drugs such as sulphobromophthalein (12) . There are insufficient data here to distinguish among the possibilities.
